Compare BHST & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHST | SEER |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.6M | 98.2M |
| IPO Year | N/A | 2020 |
| Metric | BHST | SEER |
|---|---|---|
| Price | $4.76 | $1.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 31.9K | ★ 224.6K |
| Earning Date | 03-30-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $32,720,000.00 | $16,376,999.00 |
| Revenue This Year | $116.40 | $22.37 |
| Revenue Next Year | $55.91 | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 45.88 | 12.11 |
| 52 Week Low | $4.65 | $1.62 |
| 52 Week High | $12.80 | $2.41 |
| Indicator | BHST | SEER |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 58.66 |
| Support Level | $4.82 | $1.70 |
| Resistance Level | $5.03 | $1.84 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 3.90 | 97.96 |
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.